You are here
Home > NBTXR3

Nanobiotix announces its clinical registration plan in Head and Neck cancers for the United States following FDA feedback

Moving forward with Overall Survival (OS)-based, randomized, event-driven clinical trial for the United States Pre-IND feedback from US Food and Drug Administration (FDA) provides clarity to Nanobiotix on US regulatory pathway to approval Clinical trial authorization process to begin in 2H2019 with FDA filing ‘‘We are happy to announce our plan for the registration pathway […]